Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL

Genes and Development

Volumn 22, Issue 11, 2008, Pages 1411-1415

  Mullighan, Charles G ^a   Williams, Richard T ^a   Downing, James R ^a   Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Chronic myeloid leukemia (CML); Dasatinib (Sprycel); Imatinib (Gleevec); SNP genomic microarrays; Targeted therapy

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DASATINIB; IKAROS TRANSCRIPTION FACTOR; IMATINIB; NILOTINIB; TRANSCRIPTION FACTOR PAX5;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; BLAST CELL CRISIS; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL LINEAGE; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; GENE DELETION; GENE INACTIVATION; GENE LOCUS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TREATMENT OUTCOME;

CELL LINEAGE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENES, P16; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 44849129491     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1673908     Document Type: Review

References (38)

1. Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., et al. 2000. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342: 998-1006.
2. Calabretta, B. and Perrotti, D. 2004. The biology of CML blast crisis. Blood 103: 4010-4022.
3. Castor, A., Nilsson, L., Astrand-Grundstrom, I., Buitenhuis, M., Ramirez, C., Anderson, K., Strombeck, B., Garwicz, S., Bekassy, A.N., Schmiegelow, K., et al. 2005. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 11: 630-637.
4. Chan, L.C., Karhi, K.K., Rayter, S.I., Heisterkamp, N., Eridani, S., Powles, R., Lawler, S.D., Groffen, J., Faulkes, J.G., Greaves, M.F., et al. 1987. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 325: 635-637.
5. 1-positive ALL. Science 235: 85-88.
6. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66: 9339-9344.
7. Collado, M., Blasco, M.A., and Serrano, M. 2007. Cellular senescence in cancer and aging. Cell 130: 223-233.
8. Deininger, M., Buchdunger, E., and Druker, B.J. 2005. The development of imatinib as a therapeutic agent for chronic myelogenous leukemia. Blood 105: 2640-2653.
9. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355: 2408-2417.
10. Gil, J. and Peters, G. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat. Rev. Mol. Cell Biol. 7: 667-677.
11. Gleissner, B., Gokbuget, N., Bartram, C.R., Janssen, B., Rieder, H., Janssen, J.W., Fonatsch, C., Heyll, A., Voliotis, D., Beck, J., et al. 2002. Leading prognostic relevance of the BCR-ABL translocation in adult B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99: 1536-1543.
12. Groffen, J., Heisterkamp, N., de Klein, A., Bartram, C.R., and Grosveld, G. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99.
13. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2303-2309.
14. Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., et al. 2004. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21: 843-851.
15. Jacobs, J.J.L., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
16. Jamieson, C.H., Ailles, L.E., Dylia, S.J., Muijtjens, M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K., Manz, M.G., Keating, A., et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast crisis CML. N. Engl. J. Med. 371: 634-636.
17. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354: 2542-2551.
18. Kim, W.Y. and Sharpless, N.E. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
19. Kohno, T. and Yokota, J. 2006. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: Deduction from structural analysis of breakpoints for deletions. DNA Repair (Amst.) 5: 1273-1281.
20. Krimpenfort, P., Ijpenberg, A., Song, J.Y., van der Valk, M., Nawjin, M., Zevenhoven, J., and Berns, A. 2007. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448: 943-946.
21. Lowe, S.W. and Sherr, C.J. 2003. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 13: 77-83.
22. Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.-H., et al. 2008. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 453: 110-114.
23. Nowell, P. and Hungerford, D. 1960. Chromosomes of normal and leukemic human leukocytes. J. Natl. Cancer Inst. 25: 85.
24. Nutt, S.L. and Kee, B.L. 2007. The transcriptional regulation of B cell lineage commitment. Immunity 26: 715-725.
25. Park, I.-K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
26. Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., and Weissman, I.L. 2007. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447: 725-729.
27. Rossi, D.J., Jamieson, C.H.M., and Weissman, I.L. 2008. Stem cells and the pathways to aging and cancer. Cell 132: 681-696.
28. Rowley, J.D. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243: 290-293.
29. +) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031. Blood (ASH Annual Meeting Abstracts) 110: Abstract 4.
30. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., and Sawyers, C.L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
31. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., and Sawyers, C.L. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 319-321.
32. Sherr, C.J. 2001. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2: 731-737.
33. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354: 2531-2541.
34. Valk-Lingbeek, M.E., Bruggeman, S.W., and van Lohuizen, M. 2004. Stem cells and cancer; the polycomb connection. Cell 118: 409-418.
35. Williams, R.T., Roussel, M.F., and Sherr, C.J. 2006. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. 103: 6688-6693.
36. +, Arf-null lymphoblastic leukemia. Genes & Dev. 21: 2283-2287.
37. Wong, S. and Witte, O.N. 2004. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22: 247-306.
38. Zhao, C., Blum, J., Chen, A., Kwon, H.Y., Jung, S.H., Cook, J.M., Lagoo, A., and Reya, T. 2007. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.